In my role at AstraZeneca, I am responsible for developing the medical strategy for the haematology franchise supporting the launches of Calquence (acalabrutinib) worldwide and building up capabilities for AstraZeneca’s entry into acute myeloid leukaemia, myelodysplastic syndromes and aggressive non-Hodgkin lymphomas.

I am a haematologist by training and have extensive medical knowledge of cancer and haematologic malignancies. I am passionate about patients and aim to deliver treatments that have a real impact for people living with cancer across every aspect of their disease.

I joined AstraZeneca in 2016, first as a Medical Director and then as the Oncology Business Unit Director in Argentina and Uruguay. Following this, I served as the lead of AstraZeneca’s haematology commercial team where I oversaw a cross-functional team supporting acalabrutinib in multiple geographies including Latin America, the Middle East and Asia-Pacific.

I have more than a decade of experience within the pharmaceutical industry, and previously served in medical affairs roles at Novo Nordisk A/S and Pfizer. During this time, I have gained extensive experience developing and executing portfolio / brand strategy, product launches and pricing and market access in the emerging markets.

My work is supported by more than 70 congress presentations and several peer-reviewed publications. I have also served as an investigator in more than 25 clinical trials in haemostasis, onco-haematology and infectious disease.

Prior to joining the private sector, I was trained in haematology at both Mount Sinai Medical Center in New York, and the British Hospital in Buenos Aires, where I served as an attending physician.

My experience and training as a haematologist have shaped the way I approach my work at AstraZeneca. It’s given me a solid foundation for understanding individual patient needs and taking a patient-centric approach to improve cancer care.

Carlos Doti Global Medical Affairs Head, Hematology and Ad Interim US Hematology Franchise Head, Medical Affairs


2013: Global Medical Affairs, Manager of the Year at Novo Nordisk A/S


2012: Innovation Award for development of a physician, patient and caregiver website at Novo Nordisk Pharma


2011: Innovation Award for development of scientific material for iPad at Novo Nordisk Pharma


Global Medical Affairs Head, Hematology and Ad Interim US Hematology Franchise Head, Medical Affairs

2018 - 2019

Served as Haematology Franchise Director, International Region at AstraZeneca, responsible for the franchise within Latin America, Brazil, the Middle East, Africa, Asia-Pacific, Russia and Eurasia regions

2016 - 2018

Served in various roles within AstraZeneca including as Medical Director and Oncology Business Unit Director in Argentina and Uruguay


Served as Regional Medical Director in Oncology at Pfizer in Buenos Aires

 Featured publications

Hematopoietic stem cell transplantation in the era of tyrosine kinase inhibitors.

CA Doti, EO Bullorsky. Leuk Lymphoma. 2009 Dec; 50 Suppl 2:27-31

Publication link.

Efficacy of extended thrombo-prophylaxis in major abdominal surgery: what does the evidence show? A meta-analysis.

FJ Bottaro, MC Elizondo, CA Doti, JE Bruetman, PD Perex Moreno, EO Bullorsky, JM Ceresetto. Thromb Haemost. 2008 Jun; 99(6):1104-11

Publication link.

Leukemia after liver transplant.

CA Doti, GE Gondolesi, PA Sheiner, S Emre, CM Miller, LM Aledort. Transplantation. 2001;72(10):1643-1646

Publication link.